Paclitaxel promotes lung cancer cell apoptosis via MEG3-P53 pathway activation

This study aimed to explore the effects of PTX on the expression of maternally expressed gene 3 and its anti-tumor mechanism in lung cancer cells. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays were performed to determine cell proliferation

Jianhao Xu; Cunjin Su; Fenglun Zhao; Jialong Tao; Duanmin Hu; Aiming Shi; Jie Pan; Yusong Zhang

2018

Scholarcy highlights

  • Paclitaxel is a first-line chemotherapy drug for advanced non-small cell lung cancer
  • This study aimed to explore the effects of PTX on the expression of maternally expressed gene 3 and its anti-tumor mechanism in lung cancer cells. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays were performed to determine cell proliferation
  • Quantitative polymerase chain reaction was used to determine the levels of MEG3 expressions
  • PTX significantly inhibited the proliferation of NSCLC cells and increased the expressions of MEG3 and P53
  • The inhibition of P53 caused no effect on the upstream MEG3 expression
  • Our results suggest that the MEG3-P53 pathway is involved in the apoptosis of A549 cells induced by PTX
  • Our results suggest that the maternally expressed gene 3-P53 pathway is involved in the apoptosis of A549 cells induced by PTX

Need more features? Save interactive summary cards to your Scholarcy Library.